Neural Implants Clear the FDA Gauntlet: Inside the Silicon Eating Into the Cortex

Three brain-computer interfaces just punched through the FDA's de novo pathway. The story isn't the approvals — it's the thermodynamic tightrope of running compute inside a living skull.

For two decades, brain-computer interfaces existed in a strange purgatory — too credible to dismiss as science fiction, too brittle to call medicine. That purgatory ended this quarter. The FDA's de novo pathway, the same regulatory mechanism that once midwifed the cochlear implant, has now cleared three discrete BCI candidates targeting motor restoration in ALS and high-level spinal cord injury.

The engineering story underneath the press releases is more interesting than the approvals themselves, and it is governed almost entirely by thermodynamics. A neural ASIC sitting millimeters from cortical tissue cannot exceed a roughly two-degree-Celsius local rise without provoking a cascade of glial scarring. That is why every shipping design now lives under a punishing twenty-milliwatt power envelope.

The surgical workflow is mutating in lockstep with the silicon. Neuralink's R1 robot now seats hundreds of flexible threads through a craniectomy smaller than a US dime. Synchron's Stentrode skips the craniotomy entirely, threaded up the jugular and lodged in the superior sagittal sinus.

The market layer is consolidating faster than most observers expected. The next inflection won't be another approval — it will be the FDA's post-market surveillance data trickling out across the second half of the year, which is where long-term electrode stability either holds up or quietly collapses under chronic immune response.